JAMA Psychiatry
April 15, 2026
Diana Orsini, Sabrina Wong, Sara Di Luch et al.
4 citations
In randomized clinical trials of psychedelic drugs for psychiatric disorders, the drugs' strong subjective effects often reveal which treatment participants or raters think they received, a phenomenon called functional unblinding. A systematic review of 112 trials found that only 29.5% assessed whether blinding was maintained, yet 57.1% cited blinding as a limitation. Blinding failure exceeded 90% in psilocybin, LSD, and ayahuasca studies and 85% in MDMA trials with inert placebos. Ketamine trials rarely assessed blinding but fared better when midazolam was used as an active comparator. No control strategy consistently preserved ideal blinding, raising concerns about the validity of efficacy estimates.
JAMA Psychiatry
August 1, 2021
4 citations
No Summary
JAMA Psychiatry
March 25, 2026
Wiesław Jerzy Cubała, Malek Bajbouj, Michael Bauer et al.
3 citations
A single day of treatment with an inhaled synthetic formulation of mebufotenin (GH001) significantly reduced depression symptoms in adults with treatment-resistant depression compared to placebo. In a randomized, double-blind trial of 81 patients, those receiving up to three escalating doses of GH001 showed an average 15.5-point greater improvement on the Montgomery-Åsberg Depression Rating Scale by day 8 than those on placebo. Remission rates were 57.5% for GH001 and 0% for placebo. No severe or serious adverse events occurred. The findings suggest GH001 may be a rapid-acting, well-tolerated treatment option for treatment-resistant depression.
JAMA Psychiatry
February 10, 2021
Alan K. Davis, Roland R. Griffiths
3 citations
No Summary
JAMA Psychiatry
April 10, 2024
Eiko I. Fried, Ioana A. Cristea, Florian Naudet
2 citations
A letter to the editor raises three concerns about a published study that tested 25 mg of psilocybin in 15 patients with treatment-resistant type 2 bipolar depression. The authors of the letter identify specific methodological issues with the study protocol but do not present new data or findings.
JAMA Psychiatry
December 6, 2023
David B. Yaden, Natalie Gukasyan, Sandeep M. Nayak
2 citations
No Summary
JAMA Psychiatry
March 18, 2026
1 citation
A guided psychedelic experience with psilocybin may treat refractory depression by inducing a mystical experience, rather than through a simple biological drug effect. The text suggests that the therapeutic benefit could stem from the profound, transformative nature of the experience, as conceptualized by William James.
JAMA Psychiatry
April 10, 2024
Scott T. Aaronson, Andrew van der Vaart, Harold A. Sackeïm
No Summary
JAMA Psychiatry
December 1, 2023
Chittaranjan Andrade
Ketamine, an anesthetic with a history of recreational use, is being investigated for new on- and off-label indications across medical disciplines, including treatment-resistant depression, chronic pain, and other conditions. The article discusses the expanding experimental and clinical applications of ketamine, highlighting its potential benefits and risks as research progresses.